Press Releases

ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

 –  Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant – –  Over 24-Weeks, Bempedoic Acid Was Observed to be Safe, Well-Tolerated, and the Muscle-Related Adverse Event Rate Did Not Differ from Placebo – –  Bempedoic

–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP– –Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was Similar to that of Placebo– –Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor

–  Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher Overall Adverse Events Compared With Placebo – –  Bempedoic Acid is an Oral, Once-daily ATP Citrate

ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of

ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for bempedoic acid and the bempedoic acid / ezetimibe

ANN ARBOR, Mich., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol

–     Esperion to Receive $300 Million in Upfront and Near-term Milestones    – –     Up to $900 Million in Total Milestones     – –     Substantial Tiered Royalties     – –     Esperion Partnering with a European CV Sales Organization Exceeding 1000 and One of the Most Successful European-based

ANN ARBOR, Michigan , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein